These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6807679)

  • 1. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.
    Schulman CC; Robinson M; Denis L; Smith P; Viggiano G; de Pauw M; Dalesio O; Sylvester R
    Eur Urol; 1982; 8(4):207-12. PubMed ID: 6807679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma.
    Schulman CC; Rozencweig M; Staquet M; Kenis Y; Sylvester R
    Eur Urol; 1976; 2(6):271-3. PubMed ID: 829223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study.
    Schulman C; Sylvester R; Robinson M; Smith P; Lachand A; Denis L; Pavone-Macaluso M; De Pauw M; Staquet M
    Recent Results Cancer Res; 1978; 68():338-45. PubMed ID: 111322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer.
    Br J Urol; 1994 Jun; 73(6):632-8. PubMed ID: 8032829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
    Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW
    J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does intravesical chemotherapy prevent invasive bladder cancer?
    Green DF; Robinson MR; Glashan R; Newling D; Dalesio O; Smith PH
    J Urol; 1984 Jan; 131(1):33-5. PubMed ID: 6418897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
    Br J Urol; 1985 Dec; 57(6):680-5. PubMed ID: 2867800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Instillation chemotherapy with peplomycin in superficial bladder cancer: clinical study on the effects of the direct antitumor activity and of the prophylaxis of recurrence].
    Sonoda T; Osafune M; Matsuda M; Usami M
    Hinyokika Kiyo; 1988 Mar; 34(3):574-81. PubMed ID: 2455442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.
    Bouffioux C; Denis L; Oosterlinck W; Viggiano G; Vergison B; Keuppens F; De Pauw M; Sylvester R; Cheuvart B
    J Urol; 1992 Aug; 148(2 Pt 1):297-301. PubMed ID: 1635122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma.
    Burnand KG; Boyd PJ; Mayo ME; Shuttleworth KE; Lloyd-Davies RW
    Br J Urol; 1976 Feb; 48(1):55-9. PubMed ID: 817761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of epipodophyllotoxin derivatives in bladder cancer.
    Serretta V; Ingargiola GB; Pavone-Macaluso M
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):81-4. PubMed ID: 1411641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical treatment with thiotepa: an update review.
    Fosså SD
    Prog Clin Biol Res; 1984; 162B():163-8. PubMed ID: 6438640
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.
    Kurth KH; Schröder FH; Tunn U; Ay R; Pavone-Macaluso M; Debruyne F; de Pauw M; Dalesio O; ten Kate F
    J Urol; 1984 Aug; 132(2):258-62. PubMed ID: 6376827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative doxorubicin instillation in recurrent superficial bladder cancer.
    Kubota Y; Noguchi S; Shuin T; Moriyama M; Hosaka M; Satomi Y; Furuhata A; Kondo I; Sakuramoto T; Yao M
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S56-9. PubMed ID: 3664944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 20. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.